Previous Close | 0.0500 |
Open | 0.0000 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's Range | 0.0500 - 0.0500 |
52 Week Range | 0.0300 - 0.3000 |
Volume | |
Avg. Volume | 93,375 |
Market Cap | 4.293M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Napanee, Ontario--(Newsfile Corp. - May 15, 2024) - Lophos Holdings Inc. (CSE: MESC) ("Lophos" or the "Company") proudly announces the traditional blessing of its Napanee site, paying homage to the indigenous heritage of its founders and sanctifying the grounds for the cultivation of Lophophora williamsii (peyote) moving forward.The ceremony, led by esteemed elders, holds deep significance for Lophos Pharmaceuticals Corp., a subsidiary wholly-owned by Lophos Holdings Inc. This blessing is a test
NAPANEE, Ontario, May 06, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. ("Lophos", or the "Company") (CSE:MESC) is pleased to announce that its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. (“Lophos Pharma”) - a biosciences company specializing in the cultivation, research, and sale of Lophophora williamsii (peyote), announced today that it has entered into a letter of intent to acquire the cactus cultivation business of Magicactus.com. Under the terms of the letter of intent, Lophos Pha
NAPANEE, Ontario, May 02, 2024 (GLOBE NEWSWIRE) -- Lophos Holdings Inc. ("Lophos", or the "Company") (CSE:MESC) is pleased to announce the official commencement of its first research protocol under its wholly-owned subsidiary, Lophos Pharmaceuticals Corp. The protocol, centered on the cultivation of Lophophora williamsii (Peyote), marks a significant milestone in Lophos' dedication to advancing sustainable indoor cultivation practices for this endangered species. The research protocol, developed